Repare Therapeutics Inc logo


Repare Therapeutics Inc


Earnings Summary

Net Profits


Net Profits:

Repare Therapeutics Inc’s net profit fell -44.79% since last year same period to $-38.09Mn in the Q2 2022. On a quarterly growth basis, Repare Therapeutics Inc has generated -9.6% fall in its net profits since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Repare Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
EPS Estimate Current Year


EPS Estimate Current Quarter:

Repare Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.85 - a 1.16% jump from last quarter’s estimates.

EPS Estimate Current Year:

Repare Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.85.

Key Ratios

Key ratios of the Repare Therapeutics Inc post its Q2 2022 earnings

Return on Assets (ROA)
Return on Equity (ROE)
Dividend Per Share (DPS)


Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Repare Therapeutics Inc’s return on assets (ROA) stands at -0.27.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Repare Therapeutics Inc’s return on equity (ROE) stands at -0.56.

Dividend Per Share (DPS):

Repare Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %

Company Information

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor currently in Phase 1/2 clinical development, as well as RP-6306, a CCNE1-SL inhibitor, and a Polθ inhibitor program.

Repare Therapeutics Inc
Health Technology